Immutep Receives A$4.6 million R&D Tax Incentive from French Government

Immutep Limited, a prominent immunotherapy company focused on cancer and autoimmune diseases, has announced the receipt of approximately A$4.6 million (or €2,588,954) as a research and development (R&D) tax incentive payment from the French Government. This funding comes under the Crédit d’Impôt Recherche (CIR) scheme, which allows companies conducting eligible R&D activities in Europe to recover 30% of their qualifying expenses. Immutep qualifies for this incentive through its French subsidiary, Immutep S.A.S., benefiting from R&D performed in its laboratory within France, specifically for expenditures incurred during the 2024 calendar year.

This significant cash injection is set to bolster Immutep’s ongoing and future clinical development efforts surrounding its key therapeutic candidates, eftilagimod alfa and IMP761. Furthermore, Immutep remains eligible for additional cash rebates through the Australian Government's R&D tax incentive program, further enhancing its financial resources for innovative treatments.

The company is recognized as a pioneer in the domain of Lymphocyte Activation Gene-3 (LAG-3), striving to transform the landscape of therapeutic options by stimulating or suppressing immune responses. With a commitment to maximize shareholder value while providing novel treatment alternatives, Immutep is positioned to advance its promising product portfolio.

As part of a broader strategy to leverage its expertise and capitalize on R&D opportunities, this tax incentive underscores Immutep's commitment to innovation in immunotherapy. Investors and interested parties can find more information on the company’s activities and developments at their official website, www.immutep.com. For investor inquiries, regional representatives are available for media and communication assistance.

Immutep Limited's recent announcement regarding the A$4.6 million R&D tax incentive from the French government underscores its commitment to advancing its innovative therapies targeting cancer and autoimmune diseases. The receipt of this cash payment through the Crédit d’Impôt Recherche scheme reflects both the company's strong international R&D operations and its eligibility for substantial tax rebates, which significantly bolster its financial position.

From a market perspective, this development presents a positive indicator for potential investors and current stakeholders. The cash incentive not only provides immediate liquidity but also enhances Immutep's fiscal flexibility, allowing for continued investment in the clinical development of key assets like eftilagimod alfa and IMP761. The ongoing support for these drug candidates is critical as the company navigates late-stage trials, positioning itself for potential commercial success.

Moreover, the backing of both French and Australian governments in supporting R&D activities underscores the strategic value of Immutep’s operations, potentially signaling a robust pipeline ahead. For investors, this dual eligibility for tax incentives could indicate effective financial management and a commitment to sustained innovative research.

However, investors should remain cognizant of the inherent risks associated with late-stage biotechnology investments, particularly in the highly competitive immunotherapy space. While regulatory approvals and market viability of Immutep's products stand as key catalysts for share price appreciation, any setbacks in clinical trial outcomes or regulatory scrutiny could adversely impact investor sentiment.

Overall, Immutep’s cash incentive from the French government is a strong positive for the company, providing critical resources to potentially yield long-term shareholder value. Investors may wish to consider adding Immutep to their portfolios, keeping a close watch on future clinical developments and market dynamics.